Clearmind Medicine (CMND) — Clearmind Medicine completed initiation of a leading Israeli clinical site for its Phase I/IIa trial of CMND-100 in alcohol use disorder, adding to previously activated US sites at Yale and Johns Hopkins.
The expansion widened the multinational footprint of the study evaluating safety, dosing and early efficacy signals such as reduced alcohol cravings and consumption. Consistent site build-out is an operational marker of progress for the small-cap.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.